1527-3350/asset/cover.gif?v=1&s=3cd983af6575c8dbfd6b47a63ffa95415ace15f8 "Hepatology")
Potential conflict of interest: Nothing to report.
1527-3350/asset/olbannerleft.gif?v=1&s=4b2409f9534ed500d3c8da1940a23842e2b9932d)
1527-3350/asset/olbannerright.gif?v=1&s=141b9a8485298533c3e2016e937b0404f7d933e1)
Correspondence
You have full text access to this OnlineOpen article
Reply:†
Article first published online: 5 NOV 2008
DOI: 10.1002/hep.22635
Copyright © 2008 American Association for the Study of Liver Diseases
Additional Information
How to Cite
Campos, G. M. (2008), Reply:. Hepatology, 48: 2087. doi: 10.1002/hep.22635
- †
Publication History
- Issue published online: 24 NOV 2008
- Article first published online: 5 NOV 2008
- Accepted manuscript online: 5 NOV 2008 12:00AM EST
We appreciated the interest in our article1 and the insightful comments from Dr. Enzo Emanuele. We believe that routine use of the proposed NASH scoring system, which comprises variables readily available to clinicians when they evaluate morbidly obese patients, can facilitate clinical decisions and help clinicians choose and tailor treatment for morbid obesity, including bariatric surgery. We agree with Dr. Emanuele that many other biomarkers may indeed increase the diagnostic performance of the proposed NASH scoring system. Further clinical translational research, including cost analysis, is needed to better define diagnostic and therapeutic approaches to obesity and its associated diseases.
Reference
- 1, , , et al. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. HEPATOLOGY 2008; 47: 1916–1923.
Guilherme M. Campos M.D., FACS*, * Department of Surgery, University of California San Francisco, San Francisco, CA.